Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives CHMP recommendation for Lynparza

AstraZeneca receives CHMP recommendation for Lynparza

28th October 2014

AstraZeneca has received a European regulatory recommendation for Lynparza, its promising new therapy for ovarian cancer.

The drug has been endorsed for approval as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive, relapsed, BRCA-mutated ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy.

Based on positive safety and efficacy data from a phase II clinical trial, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission grant the drug final approval.

It could become the first PARP inhibitor to be made available in Europe for the treatment of this serious form of ovarian cancer.

Briggs Morrison, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We are committed to investigating the full potential of olaparib and have a number of studies underway in multiple tumour types including breast and gastric cancer."

This follows the publication of positive results from a phase IIb study of the company's new severe asthma therapy benralizumab earlier this month.ADNFCR-8000103-ID-801756806-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.